stockrow
Saturday 7 November 2026
Export STTK’s income statement to Excel — free account
Shattuck Labs, Inc.
STTK Healthcare Biotechnology
Shattuck Labs, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.0 million, down 82.5% from fiscal 2024.
- Revenue
- −10.3%
- EPS
- +50.0%
- Free cash flow
- +1.01%
Quarter to June 2026, against a year earlier
4.59
0.10
+2.23%
Follow STTK
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 4 |
+8 more TTM periods Free account |
| (39.21%) | (61.04%) | (60.25%) | (57.84%) | ||
| (36.88%) | (55.64%) | (53.61%) | (51.77%) | ||
ROIC |
(1,230.74%) | (607.74%) | (744.34%) | (508.04%) | |
Return on Tangible Assets |
(25.03%) | (52.58%) | (59.86%) | (59.38%) | |
Average Days of Receivables |
— | — | — | 0.00 | |
Free Cash Flow per Share |
(0.32) | (0.37) | (0.57) | (0.68) | |
Free Cash Flow |
(41.24) | (41.27) | (39.99) | (48.89) | |
Capital Expenditures |
(0.21) | — | (0.11) | (0.13) | |
| Other line items | |||||
Cash ROIC |
(9.83%) | (22.16%) | (24.93%) | (27.26%) | |
Accounts Receivable Turnover |
— | — | — | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 742.28% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 306.21% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 129.13% | |
Operating CF/Net income |
0.78 | 0.83 | 0.82 | 0.89 | |
Depreciation/Fixed assets |
0.64 | 0.59 | 0.53 | 0.44 | |
Capex/Depreciation |
(0.07) | 0.00 | (0.03) | (0.04) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.08 | |
Operating CF per Share |
(0.32) | (0.37) | (0.57) | (0.68) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | — | 0.00 | 0.02 |
Columns are period end dates